CERVIX | CERVICAL SCREENING [ISSN 1804-087X]
česky | english | sitemap


PARTNERS AND EXPERT GUARANTEE
 
Czech Gynaecological and Obstetrical Society | Ministry of Health | Institute of Biostatistics and Analyses, Masaryk University
GRANT SUPPORT OF THE PROJECT
 
GlaxoSmithKline     Roche |

Other sources of information
Cervical cytology (in Czech)www.cipek.cz
Cervical cytology
 
Cancer Screening in the European Unionec.europa.eu
Cancer Screening in the European Union (2017)
[ 10,6 MB]
 
SVOD - Epidemiology of malignant tumours in the Czech Republicwww.svod.cz
Epidemiology of malignant tumours
in the Czech Republic
 
NCI Bethesda System
HPV College

 

Vaccinating girls and boys against human papillomavirus (HPV) prevents the development of several serious cancers and protects human lives

As in most developed European countries, a vaccination programme against HPV has also been introduced in the Czech Republic. HPV vaccines are reimbursed from the public health insurance if the first dose is administered between ages 13 and 14. Both girls and boys can be vaccinated under this scheme.


As for girls, HPV vaccination has been reimbursed since the 1 April 2012. The vaccination programme was extended in August 2017 to cover boys as well (by Draft Amendment to Act No. 290/2017 Coll.). The above-mentioned age interval applies to both sexes, effective from 1 January 2018.

In the spectrum of current options for cancer control, HPV vaccination actually presents a groundbreaking and unique way of preventing many serious cancers such as cervical, vulvar, anal, penile or vaginal cancer, but also oropharyngeal cancers. Approximately 150 types of HPV have been described so far, out of which about 40 affect the genital area; HPV is therefore considered to be most common sexually transmitted infection worldwide. The currently available vaccination provides a protection against the human papillomavirus, thus representing a highly effective prevention tool, which addresses the very cause of cancer development.

In the Czech population, this health issue has serious consequences on cancer epidemiology, as confirmed by the latest statistics on HPV-positive cancers, which show a steadily growing trend. In the Czech Republic, the annual incidence of HPV-associated cancers is up to 2,440 new cases (out of which almost 900 are diagnosed in men) and the prevalence (i.e. the number of persons living with the disease or its history) is more than 27,500 persons (out of which 4,900 are men). With the exception of cervical cancer, where the ongoing screening programme has contributed to a decrease in incidence, the number of HPV-positive cancer cases has been growing by 3–5% each year and, moreover, the condition also affects relatively young people. These increases in incidence have been reported in the age category as young as 30–35 years.

The press conference will sum up the availability of HPV vaccination in the Czech Republic and present the latest data on HPV vaccination coverage. The analysis of data on HPV vaccination that was reimbursed from the public health insurance shows that the HPV vaccination coverage in girls aged 13–14 reached 65% in 2017; however, considerably different rates have been reported for individual regions of the Czech Republic, ranging from 50% to 80%. The latest available data, which cover the period 2016–2017, do not allow to quantify the HPV vaccination coverage in boys, who were included in the existing vaccination scheme (i.e. reimbursed from the public health insurance) only in January 2018. In the period 2016–2017, HPV vaccination was only reimbursed for dozens of boys aged 13–14. Data on HPV vaccination paid by clients themselves are not available and the latest population-wide estimate of HPV vaccination coverage in girls aged 13–14 is therefore partially biased. However, even this estimate shows that there is still much space for improvement in this prevention effort. For this reason, it is certainly worthwhile to inform citizens on the benefits of HPV vaccination, which should ideally lead to an increase in the participation rate in the programme of reimbursed HPV vaccination.

Presentations available for download

Individual slides of all three presentations, which are suitable for on-line viewing, are available below.

HPV vaccination in the Czech Republic (July 2018)
Annex No. 1: Availability of HPV vaccination in the Czech Republic and in international comparison
Annex No. 1: Availability of HPV vaccination in the Czech Republic and in international comparison
HPV vaccination in EU member states (report from 2015)
HPV vaccination in EU member states (report from 2015)
EU member states without an HPV vaccination programme (report from 2015)
EU member states without an HPV vaccination programme (report from 2015)
Overview of vaccines against HPV that are available in the Czech Republic (J07BM)
Overview of vaccines against HPV that are available in the Czech Republic (J07BM)
Annex No. 2: Latest available data on HPV vaccination coverage of the Czech population
Annex No. 2: Latest available data on HPV vaccination coverage of the Czech population
Data source: the new National Health Information System (NHIS)
Data source: the new National Health Information System (NHIS)
Overview of NRHZS data: total number of patients with reimbursed HPV vaccination
Overview of NRHZS data: total number of patients with reimbursed HPV vaccination
Overview of medicinal products used for HPV vaccination
Overview of medicinal products used for HPV vaccination
Proportion of vaccinated patients in relation to population size (2017)
Proportion of vaccinated patients in relation to population size (2017)
Proportion of vaccinated patients in relation to population size (2017)
Proportion of vaccinated patients in relation to population size (2017)
Annex No. 3: Epidemiology of HPV-related cancers in the Czech population
Annex No. 3: Epidemiology of HPV-related cancers in the Czech population
3.1: Summary overview
3.1: Summary overview
Epidemiological overview of HPV-related cancers: absolute numbers
Epidemiological overview of HPV-related cancers: absolute numbers
Epidemiological overview of HPV-related cancers: numbers per 100,000 population
Epidemiological overview of HPV-related cancers: numbers per 100,000 population
HPV-related cancers: summary
HPV-related cancers: summary
3.2: Tabular and graphical summaries for individual cancer types
3.2: Tabular and graphical summaries for individual cancer types
Epidemiological trends for cervical cancer (C53) in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for cervical cancer (C53) in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for cervical cancer (C53) in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 women
Epidemiological trends for cervical cancer (C53) in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 women
Epidemiological trends for cervical cancer (C53) in the Czech Republic: incidence, mortality and prevalence – tabular summary
Epidemiological trends for cervical cancer (C53) in the Czech Republic: incidence, mortality and prevalence – tabular summary
Epidemiological trends for cervical cancer (C53) in the Czech Republic: age structure
Epidemiological trends for cervical cancer (C53) in the Czech Republic: age structure
Epidemiological trends for vulvar cancer (C51) in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for vulvar cancer (C51) in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for vulvar cancer (C51) in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 women
Epidemiological trends for vulvar cancer (C51) in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 women
Epidemiological trends for vulvar cancer (C51) in the Czech Republic: incidence, mortality and prevalence – tabular summary
Epidemiological trends for vulvar cancer (C51) in the Czech Republic: incidence, mortality and prevalence – tabular summary
Epidemiological trends for vulvar cancer (C51) in the Czech Republic: age structure
Epidemiological trends for vulvar cancer (C51) in the Czech Republic: age structure
Epidemiological trends for vaginal cancer (C52) in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for vaginal cancer (C52) in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for vaginal cancer (C52) in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 women
Epidemiological trends for vaginal cancer (C52) in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 women
Epidemiological trends for vaginal cancer (C52) in the Czech Republic: incidence, mortality and prevalence – tabular summary
Epidemiological trends for vaginal cancer (C52) in the Czech Republic: incidence, mortality and prevalence – tabular summary
Epidemiological trends for vaginal cancer (C52) in the Czech Republic: age structure
Epidemiological trends for vaginal cancer (C52) in the Czech Republic: age structure
Epidemiological trends for anal cancer (C21) in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for anal cancer (C21) in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for anal cancer (C21) in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 population
Epidemiological trends for anal cancer (C21) in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 population
Epidemiological trends for anal cancer (C21) in the Czech Republic: incidence, mortality and prevalence – tabular summary
Epidemiological trends for anal cancer (C21) in the Czech Republic: incidence, mortality and prevalence – tabular summary
Epidemiological trends for anal cancer (C21) in the Czech Republic: age structure
Epidemiological trends for anal cancer (C21) in the Czech Republic: age structure
Epidemiological trends for penile cancer (C60) in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for penile cancer (C60) in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for penile cancer (C60) in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 men
Epidemiological trends for penile cancer (C60) in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 men
Epidemiological trends for penile cancer (C60) in the Czech Republic: incidence, mortality and prevalence – tabular summary
Epidemiological trends for penile cancer (C60) in the Czech Republic: incidence, mortality and prevalence – tabular summary
Epidemiological trends for penile cancer (C60) in the Czech Republic: age structure
Epidemiological trends for penile cancer (C60) in the Czech Republic: age structure
Incidence trends for selected head and neck cancers (C01, C02, C04–C06, C09) in the Czech Republic
Incidence trends for selected head and neck cancers (C01, C02, C04–C06, C09) in the Czech Republic
Prevalence trends for selected head and neck cancers (C01, C02, C04–C06, C09) in the Czech Republic
Prevalence trends for selected head and neck cancers (C01, C02, C04–C06, C09) in the Czech Republic
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 population
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 population
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in the Czech Republic: incidence, mortality and prevalence – tabular summary
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in the Czech Republic: incidence, mortality and prevalence – tabular summary
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in men in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in men in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in women in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in women in the Czech Republic: incidence, mortality and prevalence – absolute numbers
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in men in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 men
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in men in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 men
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in women in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 women
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in women in the Czech Republic: incidence, mortality and prevalence – numbers per 100,000 women
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in the Czech Republic by sex: incidence, mortality and prevalence – tabular summary
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in the Czech Republic by sex: incidence, mortality and prevalence – tabular summary
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in men in the Czech Republic: age structure
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in men in the Czech Republic: age structure
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in women in the Czech Republic: age structure
Epidemiological trends for selected head and neck cancers (C01, C02, C04–C06, C09) in women in the Czech Republic: age structure

12.7.2018 Committee on Healthcare from the Chamber of Deputies of the Parliament of the Czech Republic


Back